Related Experiment Video

Updated: Feb 5, 2026

Detection of Alternative Splicing During Epithelial-Mesenchymal Transition
11:48

Detection of Alternative Splicing During Epithelial-Mesenchymal Transition

Published on: October 9, 2014

13.4K

[MET exon 14 splicing sites mutations: A new therapeutic opportunity in lung cancer]

S Baldacci1, Z Kherrouche2, C Descarpentries3

  • 1Université Lille, CNRS, UMR 8161-M3T, mécanismes de tumorigenèse et thérapies ciblées, Institut Pasteur de Lille, 59000 Lille, France; Service de pneumologie et oncologie thoracique, OncoLille, université de Lille, CHU de Lille, 59000 Lille, France.

Revue Des Maladies Respiratoires
|September 4, 2018
PubMed

Insights

MET exon 14 skipping mutations are a new class of alterations in non-small cell lung cancer (NSCLC). This review covers their mechanisms, clinical features, detection, and resistance to MET inhibitors.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Mutations causing MET exon 14 skipping are an emerging class of molecular alterations found in various cancers.
  • These specific alterations occur in 2-3% of non-small cell lung cancer (NSCLC) cases.
  • Recent publications highlight objective responses to MET tyrosine kinase inhibitors in NSCLC patients with these mutations.

Purpose of the Study:

  • To review the molecular mechanisms underlying MET exon 14 skipping.
  • To elucidate the consequences of this exon loss on MET receptor activity.
  • To summarize clinical characteristics of patients with MET exon 14 skipping mutations and discuss detection and resistance issues.

Main Methods:

  • Literature review of published studies on MET exon 14 skipping mutations.
  • Analysis of molecular mechanisms and their impact on receptor tyrosine kinase activity.
  • Synthesis of clinical data and treatment outcomes for affected patients.

Main Results:

  • MET exon 14 skipping leads to altered receptor activity and represents a targetable event in NSCLC.
  • Patients with MET exon 14 skipping mutations have shown clinical benefit from MET tyrosine kinase inhibitors.
  • Challenges in mutation detection and the emergence of resistance to MET inhibitors are key considerations.

Conclusions:

  • MET exon 14 skipping mutations are a significant molecular subtype in NSCLC.
  • Understanding these mutations is crucial for effective targeted therapy selection and management.
  • Further research is needed to optimize detection strategies and overcome treatment resistance.
Keywords:
Cancer du poumonLung cancerMETRécepteur tyrosine kinaseTargeted-therapiesThérapie cibléesTyrosine kinase receptor

More Related Videos

Identification of Alternative Splicing and Polyadenylation in RNA-seq Data08:35

Identification of Alternative Splicing and Polyadenylation in RNA-seq Data

Published on: June 24, 2021

6.5K
Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

416

Related Concept Videos

Alternative RNA Splicing02:18

Alternative RNA Splicing

Alternative RNA splicing is the regulated splicing of exons and introns to produce different mature mRNAs from a single pre-mRNA. Unlike in constitutive splicing where a single gene produces a single type of mRNA, alternative splicing allows an organism to produce multiple proteins from a single gene and plays an important role in protein diversity.
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
25.2K
RNA Splicing01:32

RNA Splicing

Splicing is the process by which eukaryotic RNA is edited before its translation into protein. The RNA strand transcribed from eukaryotic DNA is called the primary transcript. The primary transcripts that become mRNAs are called precursor messenger RNAs (pre-mRNAs). Eukaryotic pre-mRNA contains alternating sequences of exons and introns. Exons are nucleotide sequences that code for proteins, whereas introns are the non-coding regions. In RNA splicing, introns are removed and exons are bonded...
60.7K
Exon Recombination02:32

Exon Recombination

The evolution of new genes is critical for speciation. Exon recombination, also known as exon shuffling or domain shuffling, is an important means of new gene formation. It is observed across vertebrates, invertebrates, and in some plants such as potatoes and sunflowers. During exon recombination, exons from the same or different genes recombine and produce new exon-intron combinations, which might evolve into new genes. 
Exon shuffling follows “splice frame rules.” Each exon...
4.2K
Conserved Binding Sites01:49

Conserved Binding Sites

Many proteins’ biological role depends on their interactions with their ligands, small molecules that bind to specific locations on the protein known as ligand-binding sites. Ligand-binding sites are often conserved among homologous proteins as these sites are critical for protein function.
Binding sites are often located in large pockets, and if their location on a protein’s surface is unknown, it can be predicted using various approaches. The energetic method computationally...
5.2K
Mutations01:39

Mutations

Overview
94.5K
Ligand Binding Sites02:40

Ligand Binding Sites

Proteins are dynamic macromolecules that carry out a wide variety of essential processes; however, the activities of most proteins depend on their interactions with other molecules or ions, known as ligands.
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
15.1K